Hyperpolarized C13 pyruvate

N/A

Report date: 2026/04/07 20:00:20
NME

Base Information

Drug NameHyperpolarized C13 pyruvate
Drug Alias NameHyperpolarized Pyruvate (13C)[13C]pyruvateHyperpolarized [1-13C] pyruvateHyperpolarized 13C
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMagnetic resonance imaging enhancers
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaSubarachnoid Hemorrhage +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGe HealthcareUniversity Of Maryland, Baltimore
China Registration ClassN/A

Develop Information

Active CompaniesUc San FranciscoNational Institute For Biomedical Imaging And Bioengineering (Nibib)Ge Healthcare +[7] 
Inactive CompaniesUniversity Of California San Francisco
Active IndicationsSolid tumoursCentral Nervous System LymphomaSubarachnoid Hemorrhage +[12] 
Inactive IndicationsOvarian NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A